FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2– Breast Cancer
Written by
Cancer Network
Published
0
comments
0
min
The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.